Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

For each subject, the trial is expected to take 14.5 months: 2.5 months for screening and subject treatment and a further 12 months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

About Diabetic Neuropathy

Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet. This gradually evolves to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. Despite adequate treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In the period from 2000 to 2001, this translated to approximately 82,000 amputations. The American Diabetes Association estimates that there are approximately 20.8 million people with diabetes in the United States and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy. According to the Centers for Disease Control, diabetes is becoming more common in the United States. From 1980 through 2002, the number of Americans with diabetes more than doubled.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused o
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Royal Philips ... (NASDAQ: VOLC ), a global leader in catheter-based ... they have entered into a definitive merger agreement. Pursuant to ... all of the issued and outstanding shares of Volcano for ... of USD 1 billion (approx. EUR 800 million), to be ...
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... Light Sciences Oncology, Inc.,(LSO) today announced that it ... (BPH), or enlargement of the prostate, using Light,Infusion ... LSO plans to conduct a 12-patient, Phase I/II,dose-escalation ... as well as a,40-patient, Phase IIa study in ...
... Inc. (OTC,Bulletin Board: GOVX), an Atlanta based, ... and treatment of infectious,diseases, today provided an ... Phase 2 preventative human clinical trial testing ... with its AIDS vaccine. Five,successful human trials ...
Cached Medicine Technology:Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 2Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate 3GeoVax Reports Progress on Its AIDS Vaccine Technology 2GeoVax Reports Progress on Its AIDS Vaccine Technology 3GeoVax Reports Progress on Its AIDS Vaccine Technology 4GeoVax Reports Progress on Its AIDS Vaccine Technology 5
(Date:12/19/2014)... December 19, 2014 The Hermitage ... club in Southern Vermont’s Deerfield Valley, announced today that ... by classic rock songs. , Three time Grammy ... a private concert followed by a trail naming ceremony. ... trail names include: “I’m Alright” the theme song for ...
(Date:12/19/2014)... The tragic death from "rat-bite fever" of a 10-year-old San ... according to a report from the U.S. Centers for Disease ... potentially fatal illness that should be considered in persons with ... rodent exposure is reported," said a team led by Dr. ... case outlined in the report occurred in August of 2013. ...
(Date:12/19/2014)... Traveling through the same U.S. airport gate, one infected ... a four-hour time span, illustrating just how easily the ... exposures in this report were not prolonged and occurred ... the fact that measles is highly contagious," wrote a ... at the U.S. Centers for Disease Control and Prevention. ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
(Date:12/17/2014)... Providence, RI (PRWEB) December 17, 2014 ... nationally recognize private practices that have made outstanding ... and in support and progression of private practice ... the American Physical Therapy Association. , On behalf ... DPT, OCS, owner and CEO of Performance accepted ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... InfoLogix,s e-Learning Team Develops Custom, Web-Based Training Solution ... Jan. 22 InfoLogix, Inc. (Nasdaq: ... of enterprise mobility and advanced wireless asset tracking ... today it has successfully deployed an advanced clinical ...
... and by male and female doctors, study finds , , ... heart failure is influenced by the gender of the ... evaluated 1,857 patients and the treatment records of 829 ... less likely to receive guideline-recommended medications, such as angiotensin-converting ...
... Clinic today announced the launch of its culture blog, Sharing Mayo ... and employees to share their stories about what makes Mayo Clinic ... ... -- Mayo Clinic today announced the launch of its culture blog, ...
... Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter ... consumers with "Better Ways to Get Better(R)," announced today ... ended December 31, 2008, will be released after the ... conference call will be held the following morning on ...
... a Difficult Target for Pharmaceutical Companies Wishing to Grow ... From Decision ResourcesWALTHAM, Mass., Jan. 22 /PRNewswire/ -- ... and advisory firms focusing on pharmaceutical and healthcare issues, ... ranks fourth in the number of untreated HIV patients ...
... Jan. 22 In 2008, The Larry King Cardiac,Foundation, ... individuals with no health insurance, increased the number of ... and continued to expand its,national network of partner hospitals. ... funds into individual medical procedures,the Foundation helped save the ...
Cached Medicine News:Health News:InfoLogix Develops Organizational Development and Mobility Training Solution for Edward Hospital 2Health News:InfoLogix Develops Organizational Development and Mobility Training Solution for Edward Hospital 3Health News:Gender May Influence Heart Failure Treatment 2Health News:Mayo Clinic Announces Sharing Mayo Clinic Blog for Patients, Employees 2Health News:Mayo Clinic Announces Sharing Mayo Clinic Blog for Patients, Employees 3Health News:Mayo Clinic Announces Sharing Mayo Clinic Blog for Patients, Employees 4Health News:Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2009 Financial Results 2Health News:Georgia Ranks Fourth in the Number of Untreated HIV Patients in the United States 2Health News:Georgia Ranks Fourth in the Number of Untreated HIV Patients in the United States 3Health News:2008 a Year of Growth and Unprecedented Service for The Larry King Cardiac Foundation 2Health News:2008 a Year of Growth and Unprecedented Service for The Larry King Cardiac Foundation 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: